Journal of Clinical & Experimental Pharmacology

Sex-related differences in Doxorubicin-induced cardiotoxicity

2^nd International Conference and Exhibition on Pharmacology and Ethnopharmacology

May 02-04, 2016 Chicago, USA

Beshay N Zordoky

University of Minnesota, USA

Scientific Tracks Abstracts: Clin Exp Pharmacol

Abstract:

Background: Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat both hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to cardiac dysfunction and heart failure. In experimental studies, female animals have been shown to be protected against DOX-induced cardiotoxicity; however, the evidence of this sexual dimorphism is inconclusive in clinical studies. Therefore, we sought to investigate whether the genetic background could influence the sexual dimorphism of DOX-induced cardiotoxicity. Methods: Male and female Wistar Kyoto (WKY) and Spontaneous Hypertensive Heart Failure (SHHF) rats were used in this study. DOX was administered in 8 doses of 2 mg/kg/week; thereafter, the rats were followed for an additional 12 weeks. Cardiac function was assessed by trans-thoracic echocardiography, systolic blood pressure was measured by the tail cuff method, and heart and kidney tissues were collected for histopathology. Results: Female sex protected against DOX-induced weight loss and increase in blood pressure in the WKY rats, whereas it protected against DOX-induced cardiac dysfunction and the elevation of cardiac troponin in SHHF rats. In both strains, female sex was protective against DOX-induced nephrotoxicity. There was a strong correlation between DOX-induced renal pathology and DOXinduced cardiac dysfunction. Conclusions: This study highlights the importance of studying the interaction between sex and genetic background to determine the risk of DOX-induced cardiotoxicity. In addition, our findings suggest that DOX-induced nephrotoxicity plays a role in DOX-induced cardiac dysfunction.

Biography :

Beshay N Zordoky has completed his PhD in Pharmaceutical Sciences and his Postdoctoral training in Cardiovascular Research from University of Alberta, Canada. He is currently an Assistant Professor in the department of Experimental and Clinical Pharmacology, University of Minnesota, USA. He has published 28 papers inpeer-reviewed journals, one book chapter, and more than 30 abstracts. He has been serving as a reviewer and an Editorial Board Member of a number of reputable journals. His research interests include cardio-oncology, cardiovascular pharmacology, and drug metabolism.

Email: zordo001@umn.edu